Sigachi Industries Announces a Dividend After a Successful Q4

Sigachi Industries Announces a Dividend After a Successful Q4

Sigachi Industries Ends FY25 on a High Note with Strong Q4 and Dividend Announcement

Sigachi Industries Ltd, a notable Indian company in the pharmaceutical excipient and specialty chemical sector, has delivered robust fourth-quarter results for FY2024–25. The company reported a healthy year-on-year growth of 7% in net profit, powered by consistent market demand and improved operational efficiencies.
On the back of its solid performance, the company declared a 10% final dividend for its equity shareholders and revealed a strategic acquisition that is expected to boost its future business prospects and market presence in the pharmaceutical industry. 

Strong Financial Performance in Q4

For the quarter ending March 2025, Sigachi posted a net profit of ₹22.67 crore, compared to ₹21.17 crore during the same quarter last year. Revenue from operations also witnessed an encouraging rise, reaching ₹128.2 crore, which reflects a 23% increase over the previous year’s Q4 revenue of ₹104.1 crore.
This performance was largely driven by growing demand for the company’s core product, Microcrystalline Cellulose (MCC), a key ingredient used in pharmaceutical tablets and capsules. Moreover, Sigachi’s ability to effectively manage costs, ensure raw material stability, and enhance manufacturing output contributed to this positive outcome.
The company maintained strong profit margins and retained healthy cash reserves, which further supported its decision to announce the dividend.

Final Dividend Declared for FY25

The firm’s Board of Directors announced a 10% final dividend, or ₹0.10 per equity share, with a face value of ₹1. Even though the dividend seems little, it represents Sigachi’s long-term strategy for financial sustainability and shareholder returns.
The dividend payout not only reflects the company’s financial discipline but also signals investor-friendly governance. Shareholder approval for the dividend will be sought in the upcoming Annual General Meeting (AGM).

Strategic Expansion Through Acquisition

Regarding the purchase of more than 1.07 crore shares valued at ₹37.22 crore, Sigachi Industries announced the acquisition of a significant stake in Trimax Bio Sciences Pvt. Ltd. as a significant step toward diversification and capacity growth.

Trimax Bio Sciences specializes on active pharmaceutical ingredients (APIs) and intermediates. The acquisition aims to create synergies that will allow Sigachi to expand the range of its pharmaceutical goods, improve value chain integration, and reach more Indian and international clients.

The management sees this action as a component of a larger plan to change the firm from one that focuses on excipients to one that offers a wide range of pharmaceutical components.

Positive Market Sentiment and Investor Confidence

Following the announcement of strong Q4 numbers, the dividend declaration, and news of the acquisition, Sigachi’s stock witnessed a substantial increase. In recent trading sessions, the stock has risen by nearly 30% in a month, including a 20% jump over the past week alone.
Market experts attribute this bullish sentiment to the company’s consistent financial performance, low debt levels, and smart capital allocation. Many analysts believe Sigachi’s shares could continue to deliver value in the mid-cap pharma segment.

Company Overview: A Leader in Pharma Excipients

Established in 1989, Sigachi Industries started as a niche manufacturer of pharmaceutical excipients. It is currently one of India’s top manufacturers of MCC, catering to the food, cosmetics, pharmaceutical, and nutraceutical sectors.
The company exports its products to more than 40 countries, including regulated markets like the United States and Europe.
Its manufacturing plants, located in Hyderabad and Gujarat, are equipped with advanced facilities, enabling the company to meet the growing global demand for high-quality ingredients. Sigachi is also diversifying into co-processed excipients, food-grade materials, and nutraceutical formulations, expanding its market share.

Future Vision and Growth Outlook

Looking ahead, Sigachi Industries plans to become a fully integrated pharmaceutical ingredients company by adding APIs and advanced chemical intermediates to its portfolio. The acquisition of Trimax is expected to be a pivotal step in achieving this transformation.
The company also aims to increase investments in R&D, automation, and digital processes to enhance manufacturing efficiency and product innovation. With a focus on backward integration and expanding international reach, Sigachi is well-positioned to accelerate its growth trajectory over the coming years.
Analysts predict that if the company maintains its current pace, it could achieve double-digit earnings growth in the medium term, driven by new product launches, acquisitions, and operational leverage.

Conclusion

Sigachi Industries has delivered an encouraging performance to wrap up FY25, marked by increased profit, higher revenue, and strategic business moves. The declaration of a final dividend, alongside the acquisition of Trimax Bio Sciences, showcases its balanced approach to short-term profitability and long-term growth.
With strong financial fundamentals, efficient leadership, and a forward-looking business strategy, Sigachi is emerging as a key mid-cap player in the Indian pharmaceutical and chemical space.

The image added is for representation purposes only